World Journal of Endocrine Surgery

Register      Login

VOLUME 4 , ISSUE 1 ( January-April, 2012 ) > List of Articles

EDITORIAL

Molecular Targeted Drugs for Advanced Thyroid Cancer

Hiroshi E Takami

Citation Information : Takami HE. Molecular Targeted Drugs for Advanced Thyroid Cancer. World J Endoc Surg 2012; 4 (1):0-0.

DOI: 10.5005/wjoes-4-1-v

License: CC BY-NC 4.0

Published Online: 01-04-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Phase trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19.
  2. Phase trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
  3. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31.
  4. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008;26:6025.
  5. Phase dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:634s.
  6. Vandetanib for the treatment of patients with local advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.